Piper Sandler analyst Matt O\'Brien reiterated an Overweight rating and $425.00 price target on ABIOMED (NASDAQ: ABMD) on the belief ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE